GB-5012

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameGB-5012
Drug Alias Nameanti-CEACAM5 CAR T-cell therapy (Shanghai Genbase Biotechnology/Chimagen Biosciences)GB-5012
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 modulators
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsColonic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesShanghai Genbase Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChimagen Biosciences LtdShanghai Genbase Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsColonic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A